Research Reference
AICAR
AMPK activator — "exercise in a pill" (no validated human dose)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
There is no validated human dose for AICAR. The endurance and fat-loss reputation traces to a single mouse study (Narkar 2008), which dosed sedentary mice at roughly 500 mg/kg/day subcutaneously — a figure that does not scale to humans by bodyweight. The only AICAR dosing ever recorded in people is the intravenous acadesine protocol used in cardiac surgery (about 0.1 mg/kg/min), and the definitive trial testing it failed its endpoint.
AICAR (also called acadesine or AICA-riboside) is an AMP mimetic: inside the cell it is phosphorylated to ZMP, which activates AMPK, the same low-energy switch that exercise flips.
AICAR is an investigational drug not approved by the FDA and is WADA-prohibited in sport.
Side Effects & Safety
The best human safety data comes from the acadesine cardiac trials, not from fitness use:
- Hyperuricemia — AICAR metabolizes to uric acid; trials documented asymptomatic rises (relevant for gout-prone individuals)
- Transient renal effects — reversible increases in creatinine were reported
- Hypotension — infusion-related, tied to the IV route in surgery
- AMPK and cancer — unsettled — most AICAR literature is anti-proliferative, but AMPK activation can be context-dependently pro-survival for established tumors. This is an open research question.
- Unknown long-term safety — chronic AICAR use in healthy people has never been studied
- Regulatory status — never FDA-approved, sold only as a research chemical, and WADA-prohibited under S4 at all times
Research Basis
The AICAR fitness story rests on one animal paper. Narkar et al. (2008, PMID 18674809): Dosed sedentary mice at ~500 mg/kg/day and reported they ran about 44% farther than vehicle controls, via PPARδ reprogramming — the "exercise in a pill" headline. The supporting mechanism is real: AICAR raises both glucose and fatty-acid oxidation in rodent muscle through AMPK (Smith 2005, PMID 15774530), and AMPK activates PGC-1α to drive mitochondrial biogenesis (Jäger 2007, PMID 17609368).
The 500 mg/kg mouse dose cannot be converted to a human dose by simple bodyweight scaling, and no controlled human study has tested AICAR for endurance, fat loss, or performance at any dose.
The only rigorous human dosing on record is the acadesine cardiac-surgery program. The definitive Phase 3 trial, RED-CABG, infused acadesine at about 0.1 mg/kg/min in roughly 3,000 patients and found no benefit — 5.1% versus 5.0% event rates, stopped for futility (Newman 2012, PMID 22782417). That negative result is why acadesine was never approved.